Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short Term Aspirin on Fallopian Tube Changes
NCT03771651Phase 1Active, not recruiting
- Sponsor
- University of Oklahoma
- Start
- Mar 2019
- Primary completion
- May 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of aspirin in fallopian tube cancer (PFTC) and Salpingitis, sponsored by University of Oklahoma. Primary endpoints: Number of subjects who exhibited alterations in the fallopian tube immune microenvironment at 5 years, Number of subjects who exhibited less carcinogenic potential than control specimens at 5 years and 1 more. Started Mar 2019; status: active, not recruiting.
02
Drugs
aspirin
03
Conditions
fallopian tube cancer (PFTC)Salpingitis
Beyond the preview
Go deeper on NCT03771651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03771651.